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Abstract
Background: Major depressive disorder (MDD) is a common psychiatric complication of HIV/AIDS. While
considerable research has been undertaken to understand the psychosocial risk factors of MDD, there is a paucity
of data on its biological risk factors including immunological factors. To address this we undertook a study to
investigate the association between MDD and pro-inflammatory cytokines and acute phase proteins among
persons living with HIV/AIDS (PLWHA) in Uganda. We collected clinical and laboratory data on 201 PLWHA
attending two HIV clinics in central and southwestern Uganda. Clinical data included DSM-IV based MDD diagnosis,
while laboratory data included the concentrations of IL-6, TNF-α and CRP measured using ELISA. Multiple logistic
linear regression analysis was used to determine which proteins were independently significantly associated with
MDD controlling for study site, sex, age and highest educational attainment.
Results: The prevalence of MDD was 62/201 (30.8%). Adjusting for confounders, the odds of MDD increased with
increasing levels of IL-6 [each unit increase in IL-6 titres was associated with an aOR = 0.98 (95% CI, 0.97–0.99); p < 0.
001]. Participants with low levels of TNF-α were at reduced risk of MDD compared to participants with no TNF-α
[those with a TNF-α of 1- <50 pg/ml titres had an aOR = 0.35(95% CI,0.10–1.16)], but as the level of TNF-α increased,
the risk of MDD increased, and in particular participants with high levels of TNF-α (of 500 or above) were at a
significantly increased risk of MDD [e.g. those with a TNF-α of 500- < 1000 pg/ml titres had an aOR = 3.98 (95% CI,1.
29–12.33)] compared to participants with no TNF-α. There was no evidence that MDD was associated with the level
of CRP titres [aOR = 0.95 (0.78–1.15); p = 0.60)].
Conclusion: In this study, the pro-inflammatory proteins IL-6 and TNF-α were significantly associated with MDD,
while CRP was not.
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Backround
According to projections by the World Health
Organization (WHO), by the year 2030 major depressive
disorder (MDD) will result in more years of life lost to dis-
ability than any other illness [1]. HIV/AIDS is associated
with a heavy burden of MDD with studies reporting rates
of between 3 and 54% [2–8]. MDD in HIV/AIDS, apart
from impairing quality of life, is associated with faster HIV
diseases progression [9], poor adherence to anti-HIV medi-
cation [10], increased risky sexual behaviour [11] and may
lead to mortality through its association with suicidal
behaviour [2]. While a lot of work has been undertaken to
understand the psychological and social risk factors of
MDD in HIV/AIDS in the African context, there is paucity
of data on its biological risk factors including immuno-
logical mechanisms. Understanding the immunological
mechanisms underlying MDD in chronic infections such as
HIV/AIDS may provide insights that may facilitate the
development of new drug targets [12], biomarkers for diag-
nosis [13] and treatment response [14].
One of the theories that has been postulated to explain
the association between MDD and immune activation
following an infection like HIV is the ‘5-hydroxytrypta-
mine’ (5-HT) hypothesis of depression [12]. According
to this theory, immune activation (following an infection
such as HIV/AIDS) releases pro-inflammatory cytokines
such as interferon gamma (IFNγ), interleukin 6 (IL-6),
and tumor necrosis factor alpha (TNF-α) which induce
secretion of indoleamine 2, 3-dioxygenase (IDO). IDO
activation leads to lower plasma tryptophan (a precursor
of the neurotransmitter serotonin whose depletion has
been implicated in MDD) and an increased synthesis of
detrimental tryptophan catabolites (TRYCATs) such as
kynurenine, kynurenic acid, xanthurenic acid, and qui-
nolinic acid which have been shown to be depressogenic
[12]. Immune activation including increased production
of proinflammatory cytokines and acute phase proteins
has repeatedly been described in MDD. Meta-analyses
by both Howren and others(2009) and Dowlati and col-
leagues (2010) have reported an association between
MDD and increased circulating peripheral concentra-
tions of the proteins: acute phase proteins (CRP), IL-6,
and interleukin 1 (IL-1) receptor antagonist and TNFα
[15, 16]. We therefore hypothesised that MDD in HIV/
AIDS will be associated with elevated levels of proin-
flammatory cytokines and acute phase proteins. To
investigate this in the HIV situation of Uganda, we
undertook a study among ART naïve HIV positive adults
at two HIV clinics in central and south-western Uganda.
Methods
Study design
This was a cross-sectional study nested within a bigger
study that was investigating the association between
MDD and psychosocial risk factors in HIV [8, 17]. Study
participants were ART naïve patients attending two
specialised HIV clinics run by the AIDS Support
Organisation (TASO) at Entebbe (semi-urban) and
Masaka (predominantly rural) [18]. The MRC/UVRI
Uganda Research Unit (the host research institution) has
established research collaboration with these two study
clinics. Out of 1100 participants enrolled for the main
study, a random sample of 201 participants was selected
using tables of random numbers to provide plasma
samples for the immunological sub-study.
Study questionnaire
A structured standardised questionnaire administered by
trained psychiatric nurses was used to collect the socio-
demographic and clinical data for the mother study. The
following socio-demographic factors that were relevant
to the immunological sub-study were collected age,
gender, highest educational attainment, religion, employ-
ment status, marital status and socio-economic index
(SEI) which was constructed from commonly available
household items in a typical Ugandan households, with
higher scores reflecting higher socio-economic status
[19]. Clinical data collected included the CD4 count and
an assessment for major depressive disorder (MDD)
using the Mini International Neuropsychiatric interview
(M.I.N.I. Plus), a structured interview based on the
DSM-IV and ICD-10 classifications [20].
Immunological assessment
Plasma IL-6, TNF-α and CRP concentrations were mea-
sured by ELISA. Anti human TNF-α (MAb TNF3/4) and
IL-6 antibodies (MAb 13A5) were purchased from
MABTECH AB, Sweden whereas the anti human CRP
antibody (Part 842676) was purchased from Research &
Diagnostics (R &D) systems, USA.
Briefly, 96-well immunolon 2HB micro plates (Thermo
Labsystems, USA) were coated with anti human monoclo-
nal antibodies (IL-6 at 0.25 μg/ml, TNF-α at 1.5 μg/ml
and CRP at 2 μg/ml) at 100 μl per well and incubated over
night at 4 °C. The following day, the coated plates were
washed three times using 200 μl of PBS containing 0.05%
Tween, pH 7.4 (Sigma-Aldrich, USA) and blocked for 1 h
(at room temperature) with 200 μl of PBS and 0.05%
Tween 20 (Sigma-Aldrich, USA) containing 0.1% MACS
BSA buffer (Miltenyi Biotec, Germany). The stored plasma
samples were thawed on the bench, diluted using the
provided ELISA Diluent (1,2 for IL-6 and TNF-α)/Reagent
Diluent (at 1:6400 for CRP) and 100 μl added in duplicates
and then incubated at room temperature for 2 h. The
plates were washed four times with 200 μl of PBS contain-
ing 0.05% Tween 20 and 100 μl of anti human IL-6 (MAb
39C3), TNF-α (MAb TNF5) or CRP (Part 842677)
biotinylated detection antibodies (0.5 μg/ml for both IL-6
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and TNF-α then 125 ng/ml for CRP) were added and
incubated at room temperature (1 h for both TNF-α and
IL-6 and 2 h for CRP). After the plates were washed as
stated above, 100 μl of Streptavidin-HRP was added (di-
luted in incubation buffer at 1:2000 for both IL-6 and
TNF-α, and 1:200 for CRP) and incubated (1 h for both
IL-6 and TNF-α, and 20 min for CRP) at room
temperature. After further washes as stated above, 100 μl
of TMB-substrate (KPL, USA for the IL-6 and TNF-α and
R & D systems, USA for CRP) was added for colour devel-
opment. The assay reaction was stopped by adding 1 M
sulphuric acid (100 μl to the IL-6 and TNF-α and 50 μl to
the CRP) and the optical densities were measured
immediately using a microplate reader (Biotek uQuant,
USA) set to 450 nm. Any samples whose C.V were greater
than 15% were repeated.
Data analysis
Using STATA (version 12.0), the median concentrations
of TNF-a, IL-6 and CRP were computed and compared
between participants with MDD and those without
MDD. Multiple logistic linear regression analysis was
used to determine which inflammatory protein was inde-
pendently significantly associated with MDD after con-
trolling for study site, sex, age and highest educational
attainment. A p-value of ≤0.05 was considered statisti-
cally significant. Additionally, using the software Prism
Version 6.0 h, graphs were generated from this data.
Ethical considerations
The study obtained ethical approval from the Uganda
Virus Research Institute’s Science and Ethics Committee
and the Uganda National Council of Science and
Technology. Only study clinic attendees who were not
impaired in anyway and had full cognitive insight were
asked to participate in this study. Study participants who
agreed to part in this study provided written consent
after being provided with adequate information about
the study. Respondents found to have significant psychi-
atric problems were referred to the psychiatric
departments at Entebbe district hospital (at the semi-
urban site) and Masaka regional referral hospital (rural
site) for further assessment and management.
Results
Socio-demographic and clinical characteristics and their
association with MDD
Table 1 shows the socio-demographic and clinical factors
of the 201 participants in this study broken down by
whether or not they had MDD. Overall MDD prevalence
was 62 (30.8%). More than half of the participants came
from TASO Masaka and participants from Masaka were
more likely to have MDD than participants from TASO
Entebbe (41.1% vs. 18.1%). Almost 80% of participants
were female and female participants had a slightly
higher prevalence of MDD than male participants
(32.5% vs. 24.4%). About one third of participants
were aged 18–29 years, one third were aged 30–39
and one third were aged 40 or over. There was no
clear trend of MDD with age. Almost two thirds of
participants had primary level as the highest level of
education, while almost one quarter had secondary or
higher education; those with secondary or higher edu-
cation had a lower prevalence of MDD than those
with primary or no education. Half of the participants
were currently married; the prevalence of MDD was
highest among the widowed and lowest among the
currently married. Over half of the participants were
Catholic; there was no clear pattern of MDD varying
between different religions. Almost 37% of partici-
pants worked as traders, artisans or in the transport
sector, with a further 30% involved in farming or fish-
ing. MDD was highest among participants who were
unemployed or retired. The prevalence of MDD de-
creased with increasing socio-economic status. About
one quarter of participants had a baseline CD4 count
of below 350 cells/μl (and thus qualified for ART
under the then prevailing ART guidelines) with a
further quarter having CD4 counts between 350 and
499 cells/μl. There was no clear pattern of MDD
increasing or decreasing with CD4 count.
Inflammatory proteins by MDD status
Figure 1 shows the bivariate associations between the
inflammatory proteins and MDD. The IL-6 concentra-
tion was significantly higher among MDD participants
compared to those without MDD (p < 0.0001; Median
22.4 pg/ml for MDD participants n = 62 and
5.762 pg/ml for participants with no MDD n = 139;
Fig. 1B). There was a trend suggesting higher TNF-α
concentrations among MDD participants compared to
those without MDD (p = 0.0765; median 22.98 pg/ml
for MDD participants n = 62 and 12.41 pg/ml for
participants with no MDD n = 139; Fig. 1C). There
was no trend between CRP and MDD (p = 0.7499;
Fig. IA).
Multivariate analysis of the association between
immunological proteins and MDD
According to Table 2, participants in Masaka were more
likely to have MDD than those in Entebbe. There was
no evidence that gender, age or education level
influenced MDD. Adjusting for the confounders there
was no evidence that MDD was associated with the level
of CRP. IL-6 and TNF-α were associated with MDD
(Table 2) in that the odds of MDD increased with
increasing IL-6, but in a non-linear fashion. Having any
TNF-α decreases the odds of MDD, but as the level of
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TNF-α increases, the odds of MDD increase. Partici-
pants with low levels of TNF-α showed reduced risk
of MDD compared to participants with no TNF-α,
but as the level of TNF-α increase, the risk of MDD
increases, and in particular participants with high
levels of TNF-α (of 500 or above) were at a signifi-
cantly increased risk of MDD. In summary, the odds
of MDD increased with increasing levels of IL-6;
participants with low levels of TNF-α were at reduced
risk of MDD compared to participants with no TNF-
α, but as the level of TNF-α increased, the risk of
MDD increased, and in particular participants with
high levels of TNF-α (of 500 or above) were at a
significantly increased risk of MDD.
Table 1 Depression status of patients by Socio-demographic factors and CD4 counts
Factor Level No MDD (n = 139) Has MDD (n = 62) Total (n = 201)
Overall 139 (69.2%) 62 (30.8%) 201
Study Site Entebbe 73 (82.0%) 16 (18.0%) 89 (44.3%)
Masaka 66 (58.9%) 46 (41.1%) 112 (55.7%)
Sex Male 31 (75.6%) 10 (24.4%) 41 (20.4%)
Female 108 (67.5%) 52 (32.5%) 160 (79.6%)
Age (years) 18–29 51 (76.1%) 16 (23.9%) 67 (33.3%)
30–34 27 (69.2%) 12 (30.8%) 39 (19.4%)
35–39 16 (61.5%) 10 (38.5%) 26 (12.9%)
40–49 27 (56.2%) 21 (43.8%) 48 (23.9%)
50 + 18 (85.7%) 3 (14.3%) 21 (10.4%)
Education Level None 15 (62.5%) 9 (37.5%) 24 (11.9%)
Primary 86 (66.7%) 43 (33.3%) 129 (64.2%)
Secondary or higher 38 (79.2%) 10 (20.8%) 48 (23.9%)
Marital Status Current married 73 (72.3%) 28 (27.7%) 101 (50.2%)
Widowed 18 (60.0%) 12 (40.0%) 30 (14.9%)
Separated/Divorced 36 (66.7%) 18 (33.3%) 54 (26.9%)
Single 10 (71.4%) 4 (28.6%) 14 (7.0%)
Missing 2 (100%) 0 2 (1.0%)
Religion Catholic 80 (66.7%) 40 (33.3%) 120 (59.7%)
Protestant 23 (74.2%) 8 (25.8%) 31 (15.4%)
Muslim 24 (72.7%) 9 (27.3%) 33 (16.4%)
Seventh Day Adventist 3 (75.0%) 1 (25.0%) 4 (2.0%)
Born Again 9 (69.2%) 4 (30.8%) 13 (6.5%)
Employment Status Farmer/Fisherman 44 (71.0%) 18 (29.0%) 62 (30.8%)
Professional/Clerical 9 (90.0%) 1 (10.0%) 10 (5.0%)
Trader/Artisan/Transport 51 (68.9%) 23 (31.1%) 74 (36.8%)
Unemployed/Retired 12 (52.2%) 11 (47.8%) 23 (11.4%)
Student/Other 23 (71.9%) 9 (28.1%) 32 (15.9%)
Socio-economic status index <=12 26 (57.8%) 19 (42.2%) 45 (22.4%)
13–15 52 (68.4%) 24 (31.6%) 76 (37.8%)
16–19 44 (73.3%) 16 (26.7%) 60 (29.8%)
20 + 17 (85.0%) 3 (15.0%) 20 (10.0%)
CD4 count (grouped) < 250 cells/μl 20 (76.9%) 6 (23.1%) 26 (12.9%)
250–349 15 (60.0%) 10 (40.0%) 25 (12.4%)
350–499 43 (76.8%) 13 (23.2%) 56 (27.9%)
500–749 45 (68.2%) 21 (31.8%) 66 (32.8%)
> = 750 cells/μl 16 (57.1%) 12 (42.9%) 28 (13.9%)
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Discussion
This is one of the first studies from sub-Saharan Africa
that has investigated the association between pro-
inflammatory cytokines and acute phase proteins and
major depressive disorder (MDD) in HIV. In this study,
IL-6 was significantly independently positively associated
with MDD. An increase in the risk of MDD with
increasing levels of IL-6 mRNA has been reported in
previous studies undertaken in the developed world both
among persons living with HIV (PLWHA) [21] and in
other medical conditions such as cancer [22], cardiovas-
cular disease, osteoporosis [23] and among the elderly
[24]. In this study, TNF-α was significantly independ-
ently positively associated with MDD. In a systematic
review that involved 13 studies, Dowlati and colleagues
(2010) reported a statistically significant positive associ-
ation between TNF-α levels and MDD [16]. In this
study, while the overall positive association between
TNF-α levels and MDD was true at TNF-α concentra-
tions above 500 pg/ml, the relationship between TNF-α
and MDD was the reverse at TNF-α concentrations
below 500 pg/ml. This non-linear association between
TNF-α and MDD has not previously been reported.
a
c
b
Fig. 1 Association of CRP (a), IL-6 (b) and TNF-α (c) with major depressive disorder. Each symbol (triangle or circle) represents CRP, IL-6 or TNF-α
concentration in the plasma of each participant. Within each data cluster for MDD or No MDD, the middle line is the median and outer lines are
the interquartile range
Table 2 Multiple logistic linear regression model for Major
depressive disorder
Factor Level aOR (95% CI) LR P-value
Study Site Entebbe 1 (Reference Level) 0.003
Masaka 3.30 (1.46; 7.45)
Sex Male 1 (Reference Level) 0.48
Female 1.40 (0.54; 3.66)
Age (years) Per one year increase 0.981 (0.944; 1.020) 0.32
Education Level None 1 (Reference Level) 0.88
Primary 1.16 (0.38; 3.51)
Secondary 0.93 (0.25; 3.41)
CRP Per 1 million increase 0.95 (0.78; 1.15) 0.60
100/(IL-6 + 1) Per unit increase 0.979 (0.969; 0.989) <0.001
TNF-α 0 1 (Reference Level) <0.001
1 - <50 0.35 (0.10; 1.16)
50 - <500 0.31 (0.10; 0.94)
500 - <1000 3.98 (1.29; 12.33)
1000 + 7.24 (1.65; 31.82)
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In this study, there was no association between C-
reactive protein (CRP) and MDD. Previous studies have
reported conflicting results on the association between
CRP and MDD, while some studies have observed a
positive association between CRP and depressive symp-
toms [15, 25–27], others have not [28]. The relationship
between CRP and MDD appears to be further compli-
cated by sex and race. Morris and colleagues (2011) in
the USA observed a positive association between CRP
and MDD among female Caucasians but not among
male Caucasians and not among African Americans of
either sex [26]. Therefore the lack of association between
CRP and MDD observed in this study could be due to
race differences. There is however need for more African
studies to confirm this finding.
Conclusion
In conclusion, as hypothesized in this study, MDD was
generally associated with elevated pro-inflammatory pro-
teins. These results suggest a possible aetiological role for
pro-inflammatory proteins in MDD. But since this study
was cross-sectional in design, we could not determine the
direction of causality between the pro-inflammatory pro-
teins and MDD. Secondly, since we assumed that HIV and
MDD are each independently associated with inflamma-
tion, an HIV negative control group would have been
required in order to investigate the independent effect of
MDD on inflammation. To resolve these issues will in
future require the use of a longitudinal study design in
order to delineate the actual direction of causality and the
inclusion of an HIV negative control group. However con-
trary to the set hypothesis, MDD was not associated with
acute phase proteins. As discussed above this may have
been due to differences in race.
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